English
Regional settings| Spread | 0.11 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 5.21 |
| Open | 5.2 |
| 1-Year Change | 34.72% |
| Day's Range | 5.08 - 5.26 |
enVVeno Medical Corporation, formerly Hancock Jaffe Laboratories, Inc., is a medical device company. The Company is focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The Company’s lead product, VenoValve, is a surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). It is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial.
BRIEF: For the nine months ended 30 September 2021, enVVeno Medical Corp revenues was not reported. Net loss applicable to common stockholders increased 58% to $7.5M. Higher net loss reflects Research and development expenses increase of 100% to $3.9M (expense), Selling, General & Administrative Expens increase of 33% to $3.9M (expense), FV/Uls Adjust on Derivatives for Hedging decrease from $212K (income) to $0K.
